We have evaluated the
Insulin secretion in patients with noninsulin-dependent diabetes mellitus (NIDDM) has been shown to be influenced by a number of factors such as adiposity, some genetic factors, aging, physical activity, type of treatment and so forth (DeFronzo and Ferrannini, 1982; Ward et al., 1984) .
Although an inverse correlation has been shown between insulin secretion capacity and metabolic control in patients with insulin-dependent diabetes mellitus (IDDM) there are few reports on the relationship between them in those with NIDDM (LevRan et al., 1986) . When hyperglycemic stress on pancreatic B cells has persisted for a long time, it may lead to the exhaustion of the B cells, resulting in more diminished B cell function in such patients.
The purpose of the present study is to evaluate the residual B cell function in long-standing NIDDM patients and to examine its relation to long-term metabolic control. Furthermore, since it was reported that the persisting residual B cell function would be associated with a decreased incidence of diabetic complications in longstanding IDDM (Eff et al., 1978; Sjoberg et al., 1987) , we also examined the relationship between the residual B cell function and the chronic diabetic complications. Fig. 3 . The relationship of the increase in serum C-peptide after glucagon administration to fasting blood glucose at the first attendance (A, r= -0.28, ns), the average of the annual mean fasting blood glucose for the observation period (mean, 21 years) (B, r= -0.13, ns) or fasting blood glucose at the glucagon load test (C, r= -0.23, ns) .
Subjects and Methods

Discussion
The glucagon load test has been widely used to evaluate the residual pancreatic B cell function because of its simplicity and reproducibility.
Although Faber et al., proposed that serum C-peptide at 6 minutes after glucagon administration could reflect the residual B cell function (Faber and Binder, 1977) , we used the increase in Cpeptide at 6 minutes after glucagon administration as an index of residual B cell function because some of the patients had been treated with insulin for a long time and the presence of insulin antibody interfering with C-peptide radioimmunoassay was expected (Maruyama et al., 1979) . Serum C-peptide response to glucagon in patients treated with sulfonylurea or insulin in the present study was substantially the same as the reported values (Matsuda et al., 1985) and it was suggested that the residual B cell function was not lowered in long-standing NIDDM, being consistent with previous studies (Lev-Ran et al., 1986; Snehalatha et al., 1986) . Some reports on IDDM indicated that the more active the residual B cell function, the better the metabolic control (Gonen et al., 1979; Clarson et al., 1987; Sjoberg et al., 1987) . The present study on NIDDM, however, differed from them in that the residual B cell function did not significantly correlate with the glycemic levels at the first visit, through the observation period and at present. The reason for this difference may be that in NIDDM patients other factors except endogenous insulin secretion such as insulin resistance play a major role in metabolic control.
Furthermore, since this study was undertaken in a retrospective manner, a number of biases did exist, for example, very poorly controlled patients could not survive for 20 years or more. However, the present study showed that NIDDM patients with poor residual B cell function could be controlled as well as those with good residual B cell function regardless of their initial hyperglycemia.
In long-standing IDDM patients, the persisting residual B cell function is associated with a decreased incidence of proliferative retinopathy (Eff et al., 1978) or proteinuria (Sjoberg et al., 1987) . In the present study, however, the prevalence of retinopathy which needed photocoagulation therapy and neuropathy was not increased in NIDDM patients with poor residual B cell function compared with those with good residual B cell function and the diabetic complications could develop even though the pancreatic B cell function was well preserved . In con-trast, glycemic control during the observation period was associated with the prevalence of diabetic complications.
Therefore, diabetic retinopathy and neuropathy were related with long term metabolic control but not with the residual B cell function in long-standing NIDDM patients.
In conclusion, the residual B cell function assessed by glucagon load test in longstanding NIDDM patients was correlated with the type of treatment and BMI but not with the long term glycemic level, and it had no direct relationship to the prevalence of diabetic complications such as advanced retinopathy and neuropathy.
Therefore, it was suggested that the residual B cell function was not a predominant determinant for glycemic control and diabetic complications in NIDDM patients, in contrast with IDDM patients.
